Moderna is broadening the company’s vaccine horizons once again using mRNA technology, widely known for its use in COVID-19 vaccinations. Moderna announced two new vaccine development programs targeting a variety of viruses.
Moderna announced that the first participant was dosed in a Phase I trial of the company’s HIV trimer mRNA vaccine, mRNA-1574.
Maryland-based Altimmune is discontinuing research into the clinical-stage biopharmaceutical firm’s intranasal Covid-19 vaccine following “disappointing” results.
Merck reported positive results regarding the safety, tolerability and immunogenicity in two Phase III studies for V114, the company’s investigational 15-valent pneumococcal conjugate vaccine.
Arcturus Therapeutics Holdings Inc. said the first group of participants were dosed in an early-stage trial testing the company’s Covid-19 vaccine candidate and that results from the trial were expected in fourth-quarter 2020.
Beijing-based Sinovac Biotech announced positive early data from a Phase I/II clinical trial of the company’s COVID-19 vaccine, CoronaVac.
Pfizer and Germany-based BioNTech, which are collaborating on a messenger RNA vaccine against SARS-CoV-2, plan to start testing in the United States once the Food and Drug Administration gives clearance.
Gaithersburg, Maryland-based Novavax announced positive topline data from the company’s pivotal Phase III clinical trial of the seasonal flu vaccine NanoFlu.
Pfizer announced positive results from two Phase III trials, one in moderate-to-severe atopic dermatitis and another in pneumococcal disease.
